Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574502 | 1.00 | MLYCD (0.32) | MLYCDMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL26151827 | 0.80 | MLYCD (0.35) | MLYCDMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL4547932 | 0.77 | FFAR2 (0.37) | MLYCDFFAR2TRPM5 | |
| SCHEMBL27481151 | 0.76 | MLYCD (0.36) | MLYCDKMT2AFFAR2KCNK3 | |
| SCHEMBL21843830 | 0.70 | MLYCD (0.34) | MLYCDFFAR2 | |
| SCHEMBL24959066 | 0.70 | MLYCD (0.34) | MLYCD | |
| SCHEMBL20098867 | 0.67 | TRPM5 (0.42) | MLYCDFFAR2TRPM5 | |
| SCHEMBL15157395 | 0.67 | SLC6A4 (0.36) | — | |
| SCHEMBL17574565 | 0.67 | DAO (0.36) | — | |
| SCHEMBL15166035 | 0.67 | NPSR1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-9284333-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-03-15 | — | — | US | disclosed |
| US-9284333-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-03-15 | — | — | US | disclosed |
| WO-2013113860-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | KCNA1, KCNE1, KCNH1 | MLYCD 1140/4885MEN1 1920/4885CYP1A2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.